Doctors who helped develop heart drug now balk at $225,000/year price

19 November 2019 - Wearing a revolutionary-era tricorn hat, doctor Mathew Maurer stood at a lectern in front of an ...

Read more →

Allogeneic hematopoietic cell transplantation and other expensive cellular therapies: a miracle for the few but off limits to many?

15 November 2019 - The number of patients undergoing allogeneic hematopoietic cell transplantation (HCT) for treatment of malignant and nonmalignant disorders ...

Read more →

Top GOP senator: drug pricing action unlikely before end of year

19 November 2019 - Senator John Thune, the Senate’s No. 2 Republican, said Tuesday that it is unlikely the Senate ...

Read more →

FDA approves first treatment for inherited rare disease

20 November 2019 - Today, the U.S. FDA granted approval to Givlaari (givosiran) for the treatment of adult patients with acute ...

Read more →

Alkermes submits new drug application to U.S. FDA for ALKS 3831 for treatment of schizophrenia and bipolar I disorder

19 November 2019 - Alkermes today announced that it has submitted a new drug application to the U.S. FDA seeking ...

Read more →

Newron receives FDA rare paediatric disease designation for sarizotan for the treatment of Rett syndrome

19 November 2019 - Newron announced today that the U.S. FDA has granted the rare paediatric disease designation for sarizotan, ...

Read more →

Generic drug approvals soar, but patients still go without

19 November 2019 - Brand name makers’ patent action limits release of the lower-price medicines, hindering cost-control efforts. ...

Read more →

Orphazyme receives breakthrough therapy designation for arimoclomol in Niemann-Pick disease Type C

19 November 2019 - Orphazyme today announces that the US FDA has granted breakthrough therapy designation for arimoclomol, an investigational drug ...

Read more →

FDA accepts Samsung Bioepis’ BLA for SB8 bevacizumab biosimilar candidate

19 November 2019 - Samsung Bioepis today announced that the U.S. FDA has accepted for review the company’s biologics license ...

Read more →

In a rare political move, prominent biotech venture capitalists speak out against Pelosi’s drug pricing bill

18 November 2019 - A group of top biotech venture capitalists are issuing a stark warning to Congress: They won’t ...

Read more →

AMA develops Rx for drug prices that are high and rising

19 November 2019 - Arbitration in determining prescription drug prices is a viable mechanism to address the burden of high and ...

Read more →

Here’s why pharmaceutical companies raise their prices so much

19 November 2019 - Yes, I’ve ranted about healthcare prices before. On more than one occasion.  ...

Read more →

AMA sharpens policy to promote reasonable drug prices

18 November 2019 - Arbitration in determining prescription drug prices is a viable mechanism to address the burden of high ...

Read more →

Elizabeth Warren says ‘Medicare for All’ rollout process will take 3 years

16 November 2019 — Elizabeth Warren announced Friday that she would expand public health insurance during her first 100 days ...

Read more →

Drug cost legislation gets a push from White House

18 November 2019 - The White House is ramping up its push to get a bill through Congress that curbs ...

Read more →